

RECEIVED  
CENTRAL FAX CENTER

MAY 24 2007

File No.: 16051-4US CC/jl

Montréal (Québec) Canada  
May 24, 2007IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Andrew Vaillant et al.  
Application No.: 10/661,403  
Filing Date: September 12, 2003  
Title: "ANTIVIRAL OLIGONUCLEOTIDES"  
Agent of Record: Christian Cawthorn Telephone: (514) 847-4256

Mail Stop 16  
COMMISSIONER FOR PATENTS,  
P.O.Box 1450  
Alexandria, VA 22313-1450  
U.S.A.

BY FACSIMILE 1- 571-273-8300

Sir:

For the above-identified application, a Terminal Disclaimer was electronically filed on May 14, 2007. We enclose a copy of the acknowledgement receipt wherein the Terminal Disclaimer fee was paid as a Large Entity, however our client is a Small Entity, we therefore request a refund of \$65.00 covering the overpayment of this fee.

The Commissioner is hereby authorized to credit the overpayment to Account No. 19-5113.

Respectfully submitted,  
Andrew Vaillant et al.

By: 

Christian Cawthorn (Reg. No. 47,352)  
Agent of Record  
Ogilvy Renault  
1981 McGill College Avenue  
Suite 1600  
Montréal, Québec, Canada H3A 2Y3  
Tel: (514) 847-4256

06/07/2007 MGE BREM1 00000001 195113 10661403  
01 FC:2814 65.00 DA

Patent Electronic Filing

Page 1 of 2

**Acknowledgement Receipt**

The USPTO has received your submission at 17:19:23 Eastern Time on 14-MAY-2007 by Deposit Account: 195113.

\$ 130 fee paid by e-File via RAM with Confirmation Number: 971.

You have also pre-authorized the following payments from your USPTO Deposit Account:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17

**eFiled Application Information**

EFS ID	1773500
Application Number	10661403
Confirmation Number	6672
Title	Antiviral oligonucleotides
First Named Inventor	Andrew Vaillant
Customer Number or Correspondence Address	20988
Filed By	Christian Cawthorn
Attorney Docket Number	16051-4US
Filing Date	12-SEP-2003
Receipt Date	14-MAY-2007
Application Type	Utility

207 MAY 25 PM 4:59

**Application Details**

Submitted Files	Page Count	Document Description	File Size	Warnings
0887_001.pdf	2	Terminal Disclaimer Filed	49414 bytes	◆ PASS
fee-info.pdf	2	Fee Worksheet (PTO-06)	8115 bytes	◆ PASS

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary

05/24/07 15:01 FAX 514 286 5474

OGILVY RENAULT

0005

Patent Electronic Filing

Page 2 of 2

components for an International filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

*If you need help:*

- Call the Patent Electronic Business Center at (866) 217-9197 (toll free) or e-mail [EBC@uspto.gov](mailto:EBC@uspto.gov) for specific questions about Patent e-Filing.
- Send general questions about USPTO programs to the [USPTO Contact Center \(UCC\)](#).
- If you experience technical difficulties or problems with this application, please report them via e-mail to [Electronic Business Support](#) or call 1 800-786-9199.

2007 MAY 25 11 4: 59

05/24/07 15:01 FAX 514 288 5474

OGILVY RENAULT

001

**OGILVY  
RENAULT**  
LP / SEN.CRL, s.r.l.**Facsimile****RECEIVED  
CENTRAL FAX CENTER  
MAY 24 2007****Confidentiality Message**

This communication sent by facsimile is confidential, may be privileged and is intended for the exclusive use of the addressee. Any other person is strictly prohibited from disclosing, distributing or reproducing it. If the addressee cannot be reached or is unknown to you, please destroy this message and all copies. Thank you.

Number of pages including this cover sheet: 5  
Date: May 24, 2007  
From: Christian Cawthorn/jl  
Telephone: (514) 847-4256  
Direct Fax: (514) 288-8389  
E-Mail: ccawthorn@ogilvyrenault.com

To	Company - City	Fax
Commissioner of Patents	U.S. Patent & Trademark Office	1-571-273-8300

**RE:**

Applicants: Andrew VAILLANT et al.  
Serial number: 10/661,403  
Filing date: September 12, 2003  
For: ANTIVIRAL OLIGONUCLEOTIDES  
Art Unit: 1648  
Examiner: Sharon L. HURT

2007 MAY 25 AM 4:59

Barriers & Solicitors,  
Patent Agents & Trade-mark Agents

Suite 1600  
1981 McGill College Avenue  
Montreal, Quebec H3A 2Y3  
Canada

Telephone (514) 847-4747  
Fax (514) 288-8389

ogilvyrenault.com

Electronic Patent Application Fee Transmittal				
Application Number:		10661403		
Filing Date:		12-Sep-2003		
Title of Invention:		Antiviral oligonucleotides		
First Named Inventor/Applicant Name:		Andrew Vaillant		
Filer:		Christian Cawthorn		
Attorney Docket Number:		16051-4US		
Filed as Large Entity				
Utility Filing Fees				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:		Adjustment Date: 06/07/2007 MGBREM1 05/15/2007 INTEFSW 00000971 195113 10661403 01 FC:1014 130.00 CR		
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Statutory disclaimer	1814	1	130	130
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
Total in USD (\$)				130